Excess accumulation and aggregation of toxic soluble and insoluble amyloid-β species in
the brain are a major hallmark of Alzheimer's disease. Randomized clinical trials show …

Alzheimer disease (AD) is the most common cause of dementia. The prevailing theory of the
underlying pathology assumes amyloid accumulation followed by tau protein aggregation …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

Cerebral Hemorrhages after t-PA in a Patient Treated with Lecanemab A patient with mild
cognitive impairment who was treated in the extension phase of a trial of lecanemab, an …

Alzheimer disease (AD) is the most common form of dementia worldwide. Treatment of AD
has mainly been focused on symptomatic treatment until recently with the advent and …

Please see the Editorial Comment by Can Ozutemiz discussing this article. Amyloid-related
imaging abnormalities (ARIA) is a term introduced in 2010 to encompass a spectrum of MRI …

With recent data demonstrating that lecanemab treatment can slow cognitive and functional
decline in early symptomatic Alzheimer disease (AD), it is widely anticipated that this drug …

The targeting of amyloid-beta (Aβ) plaques therapeutically as one of the primary causes of
Alzheimer's disease (AD) dementia has been an ongoing effort spanning decades. While …

Importance Amyloid-related imaging abnormalities (ARIA) are brain magnetic resonance
imaging (MRI) findings associated with the use of amyloid-β–directed monoclonal antibody …

Background and Objectives Amyloid-related imaging abnormalities (ARIA) were the most
common adverse events reported in the phase 3 ENGAGE and EMERGE trials of …